VITRUVIAE and Academic Collaborators Deliver Oral Presentation at ASH 2024

At the 66th American Society of Hematology (ASH) Annual Meeting in December 2024, Dr. Ashley Varkey unveiled compelling data on VITRUVIAE's novel T-cell engager, demonstrating robust preclinical efficacy in targeting hematologic malignancies with an excellent safety profile.

These findings position VItRUVIAE's T-cell engager as a promising candidate for further clinical development in the treatment of B-cell malignancies.

Read the full abstract here.